Telomir Pharmaceuticals recapped its presentation of compelling pre-clinical data on Telomir-1 at a high-profile event hosted at the National Press Club in Washington, D.C., on April 15, 2024. Dr. Chris Chapman, Co-founder, Chairman, CEO, President and Chief Medical Officer of Telomir, and Dr. Michael Roizen, special advisor to Telomir on age reversal, spearheaded the presentation, showcasing the remarkable prospects for Telomir- 1 to potentially allow the body to repair itself and mitigate effects typically associated with aging. As part of its commitment to transparency and openness in sharing its research data, during the event, Drs. Chapman and Roizen presented company data that showed the effect of Telomir-1, a novel molecule designed to modulate telomerase activity and elongate telomeres. The data show that telomeres lengthened in vitro in human cells and telomerase activity increased by 40%.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TELO:
- Telomir Pharmaceuticals Unveils Compelling Pre-clinical Data on Age-Reversal Drug Telomir-1 at National Press Club Event in Washington, D.C.
- Telomir Pharmaceuticals Unveils Research Direction at NPC
- Telomir Pharmaceuticals’ anti-aging expert to present pre-clinical data
- Telomir Pharmaceuticals’ Anti-Aging Expert and NYT Bestselling Author Michael F. Roizen, MD, to Present Promising Pre-Clinical Data for Age-Reversal Drug Telomir-1 at the National Press Club in Washington, DC, on April 15, 2024
- UPDATE – Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines